Suppr超能文献

嗜铬粒蛋白 A 在小胰腺神经内分泌肿瘤中的预后意义。

Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors.

机构信息

Department of Surgery, City of Hope National Medical Center, Duarte, CA.

Department of Surgery, University of California, Irvine, CA.

出版信息

Surgery. 2019 Apr;165(4):760-766. doi: 10.1016/j.surg.2018.10.018. Epub 2018 Nov 15.

Abstract

BACKGROUND

The incidence of nonfunctional pancreatic neuroendocrine tumors ≤2cm is rising. The biologic behavior of these tumors is variable; thus, their management remains controversial. Chromogranin A upregulation is a useful diagnostic biomarker of neuroendocrine tumors; however, the prognostic significance of Chromogranin A is unclear. The objective of this study was to determine whether Chromogranin A levels have prognostic value in pancreatic neuroendocrine tumor patients and may help guide management.

METHODS

We evaluated the National Cancer Database over a 10-year period (2004-2013). Patients with pancreatic neuroendocrine tumors measuring ≤2cm, without distant metastases, were identified and categorized as Chromogranin A high (>420ng/mL) or Chromogranin A low (≤420ng/mL), and those lacking data on Chromogranin A levels were excluded from the study. Univariate and multivariate analyses were performed using Cox proportional hazards model. Cut-point determination was performed using the Contal and O'Quigley method.

RESULTS

Of the 445 eligible patients, 352 (79%) were Chromogranin A low and 93 (21%) were Chromogranin A high. Median Chromogranin A level was 71ng/mL (interquartile range, 24-294ng/mL). Chromogranin levels were associated with clinical nodal status and grade. Furthermore, on multivariate analysis, Chromogranin A levels (Chromogranin A high versus Chromogranin A low) independently predicted overall survival after controlling for tumor size, grade, clinical nodal status, and academic status of the facility (hazard ratio: 7.90, 95%CI: 2.34-26.69, P = .001). The greatest benefit of surgical resection was noted in patients in the Chromogranin A high subgroup (log-rank P <.001).

CONCLUSION

Serum Chromogranin A levels can be incorporated in surgical decision-making for patients with small pancreatic neuroendocrine tumors. Patients in the Chromogranin A low group can be considered for observation, whereas patients in the Chromogranin A high group should be strongly considered for resection.

摘要

背景

功能性胰腺神经内分泌肿瘤≤2cm 的发病率正在上升。这些肿瘤的生物学行为具有变异性,因此其治疗方法仍存在争议。嗜铬粒蛋白 A 上调是神经内分泌肿瘤的一种有用的诊断生物标志物;然而,嗜铬粒蛋白 A 的预后意义尚不清楚。本研究旨在确定嗜铬粒蛋白 A 水平在胰腺神经内分泌肿瘤患者中是否具有预后价值,并可能有助于指导治疗。

方法

我们在 10 年期间(2004-2013 年)评估了国家癌症数据库。确定了无远处转移、肿瘤直径≤2cm 的胰腺神经内分泌肿瘤患者,并将其分为嗜铬粒蛋白 A 高(>420ng/mL)或嗜铬粒蛋白 A 低(≤420ng/mL)组,且缺乏嗜铬粒蛋白 A 水平数据的患者被排除在研究之外。使用 Cox 比例风险模型进行单变量和多变量分析。使用 Contal 和 O'Quigley 方法进行临界点确定。

结果

在 445 名符合条件的患者中,352 名(79%)为嗜铬粒蛋白 A 低,93 名(21%)为嗜铬粒蛋白 A 高。中位嗜铬粒蛋白 A 水平为 71ng/mL(四分位距,24-294ng/mL)。嗜铬粒蛋白水平与临床淋巴结状态和分级相关。此外,多变量分析表明,在控制肿瘤大小、分级、临床淋巴结状态和医疗机构学术地位后,嗜铬粒蛋白 A 水平(嗜铬粒蛋白 A 高与嗜铬粒蛋白 A 低)独立预测总生存(风险比:7.90,95%CI:2.34-26.69,P=0.001)。在嗜铬粒蛋白 A 高亚组中,手术切除的获益最大(对数秩检验 P<0.001)。

结论

血清嗜铬粒蛋白 A 水平可纳入小胰腺神经内分泌肿瘤的手术决策。嗜铬粒蛋白 A 低组患者可考虑观察,而嗜铬粒蛋白 A 高组患者应强烈考虑切除。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验